Associations Between Statin Adherence Level, Health Care Costs, and Utilization

Zhao, Yongming; Zabriski, Steve; Bertram, Carl T

doi:10.18553/jmcp.2014.20.7.703

Cited by 23 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since previous research has shown an association between statin use and reduced health care costs, 19 we also found that patients with statin use at the end of the index episode had reduced first MACE costs, which may indicate a reduction in cardiovascular complications associated with statin use. 20 Furthermore, the increased first MACE costs found among patients with an early MACE (within 3 months of the index ACS hospital discharge) warrant further exploration, with an emphasis on characterizing the event severity and treatment profile of the index ACS and subsequent MACE episodes.…”

Section: Logistic Regressions Evaluating Association Between Occurrensupporting

confidence: 72%

Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events

Korsnes¹,

Davis²,

Ariely³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

Section: Logistic Regressions Evaluating Association Between Occurrensupporting

confidence: 72%

Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events

Korsnes¹,

Davis²,

Ariely³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

“…For all conditions, the total healthcare costs were higher for non-adherent groups compared with adherent. While Zhao et al 80 categorised participants into adherence subgroups, finding that total healthcare costs were lower for the non-adherent population. The remaining studies used five key indicators to determine the economic impact: inpatient costs, 66 92 outpatient costs, 66 92 pharmacy costs, 66 94 95 medical costs 94 95 and hospitalisation costs.…”

Section: Resultsmentioning

confidence: 99%

Economic impact of medication non-adherence by disease groups: a systematic review

et al. 2018

View full text Add to dashboard Cite

ObjectiveTo determine the economic impact of medication non-adherence across multiple disease groups.DesignSystematic review.Evidence reviewA comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist.ResultsSeventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to ‘all causes’ non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents.ConclusionMedication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required.PROSPERO registration numberCRD42015027338.

show abstract

“…Patients with statin intolerance were less likely to reach LDL-C goals, incurred higher healthcare costs and experienced a higher rate of adverse cardiovascular events compared with controls. Another retrospective cohort study demonstrated a significantly higher frequency of visits to the ER, and higher total healthcare costs, in patients with low adherence to statin therapy (defined as medication possession ratio <40%) over a 1-year follow-up period after treatment initiation [10].…”

Section: Discussionmentioning

confidence: 99%

“…This includes 'desired' healthcare resource consumption, eg, that associated with patient follow-up, which aims to improve patient outcomes, and 'avoidable' consumption of healthcare resources, resulting from clinical complications of dyslipidemia. 'Avoidable' consumption may be higher in patients whose management is suboptimal, ie, difficult-to-treat patients [9,10]. Recent large-scale studies of achievement of LDL-C goals in patients with dyslipidemia have been conducted largely in Western Europe and North America [11][12][13], and data from other parts of the world are limited [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS)

et al. 2020

View full text Add to dashboard Cite

Background: Few recent large-scale studies have examined healthcare consumption associated with dyslipidemia in countries outside Western Europe and North America. Methods: This analysis, from a cross-sectional observational study conducted in 18 countries in Eastern Europe, Asia, Africa, the Middle East and Latin America, evaluated avoidable healthcare consumption (defined as ≥1 hospitalization for cardiovascular reasons or ≥1 visit to the emergency room for any reason in the previous 12 months) in patients receiving stable lipid-lowering therapy (LLT). A total of 9049 patients (aged ≥18 years) receiving LLT for ≥3 months and who had had their low-density lipoprotein cholesterol (LDL-C) value measured on stable LLT in the previous 12 months were enrolled between August 2015 and August 2016. Patients who had received a proprotein convertase subtilisin/kexin type 9 inhibitor in the previous 6 months were excluded. Patients were stratified by cardiovascular risk level using the Systematic Coronary Risk Estimation chart for high-risk countries.

show abstract

Associations Between Statin Adherence Level, Health Care Costs, and Utilization

Cited by 23 publications

References 25 publications

Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events

Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events

Economic impact of medication non-adherence by disease groups: a systematic review

Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS)

Contact Info

Product

Resources

About